|Cell Therapy Yields Promising Results For Scleroderma Treatment|
|Tuesday, 24 September 2013 08:19|
Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous Systemic Scleroderma in France.
12 patients were administered Cytori's cell therapy, injected into their fingers. Safety and hand function improvement are the primary endpoints of the study which were measured by the Cochin hand functional scale at six months.
At the end of the two month follow-up period, no infection, ischemic complications or serious adverse events were observed. Moreover, there was a significant improvement in the Cochin hand function disability scale.
As far as secondary endpoints are concerned, there was a significant improvement in Scleroderma health assessment questionnaire score and in Raynaud's Severity Score. Also, there was a significant improvement in hand pain when measured by the visual analog pain scale.
Cytori is focused primarily on the development of treatments for cardiovascular disease and soft tissue injuries and burns based on its proprietary cell therapy formulation. The company's cell therapy is based on the formulation of stem and regenerative cells derived from a patient's own adipose (fat) tissue (ADRCs).
Source: NASDAQ (2013)